| Similar Articles |
|---|
 |
Reason
January 2002
Jacob Sullum |
Sex, Drugs, and Techno Music Why the rap against Ecstasy has a familiar ring to it   |
Salon.com
June 14, 2000
Liz O'Brien |
The agony after ecstasy I took the drug for nearly a year to lift myself to euphoria. Then I crashed hard. |
Salon.com
February 5, 2001
Janelle Brown |
The disunited states of ecstasy At an all-day conference on MDMA, ravers, researchers and anti-drug crusaders debate its pros and cons. Consensus? Just say maybe... |
Reason
June 2005
Jacob Sullum |
Psychedelic Revival Psychedelic research is returning to Harvard, where psychiatrist John Halpern plans to give MDMA (a.k.a. Ecstasy) to late-stage cancer patients to relieve their anxiety and to help them come to terms with death. |
Salon.com
September 1, 2000
Eric Sabo |
Chemical ravings Worried that ecstasy may fry the serotonin cells in their brains, some ravers are taking Prozac. |
Salon.com
June 15, 2000
Ted Oehmke |
The war on information Congressional anti-drug legislation could make it illegal to give life-saving advice about ecstasy. |
The Motley Fool
October 27, 2010
Ralph Casale |
Companion Diagnostics in Cancer Drug Development Diagnostic companies partnering with drug developers can make for an attractive investment segment. |
The Motley Fool
July 30, 2010
Brian Orelli |
A Faster Pathway to Drug Approvals A thinktank called the Pacific Research Institute has proposed letting drugs approved by the European Medicines Authority onto the market in the U.S. before the Food and Drug Administration has approved the drugs. |
Chemistry World
June 12, 2013
Maria Burke |
'Scientific censorship' hamstringing psychoactive drug research Legal controls on psychoactive drugs have hindered neuroscience research and the discovery of new treatments for brain disorders in 'one of the most scandalous examples of scientific censorship in modern times', claim researchers. |
Chemistry World
May 15, 2009
Katrina Megget |
Tripping over red tape The UK may be moving a step closer to allowing the use of a cannabis-based drug to treat the symptoms of multiple sclerosis |
Salon.com
July 6, 2000
Ted Oehmke |
The poisoning of suburbia An 18-year-old girl died after taking a pill she thought was ecstasy. Is her death a sign of more tragedies to come? |
American Family Physician
June 1, 2004
Gahlinger |
Club Drugs: MDMA, Gamma-Hydroxybutyrate (GHB), Rohypnol, and Ketamine About club drugs, outcomes of ingestion and treatments after ingestion. |
Salon.com
October 10, 2000
Arthur Allen |
The drug war's Tweedledee Does National Institute on Drug Abuse chief Alan Leshner push propaganda over science in his close coordination with drug czar Barry McCaffrey? |
Reason
October 2004
Michael Erard |
Open Secrets How the U.S. government lost the drug war in cyberspace. |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
Nursing
June 2010
Daniel A. Hussar |
New drugs 2010, part 2 In this article, you'll learn about 14 recently marketed new drugs. |
Wired
September 2002
Ethan Brown |
Professor X Alexander Shulgin made millions for Dow Chemical. Then he synthesized MDMA, realized his best test subject was himself, and became the godfather of Generation Ecstasy. Now he's back inside his private lab, running a new batch of psychedelic compounds through his chromatograph. |
The Motley Fool
March 8, 2010
Brian Orelli |
Really? A 59% Share Price Jump for That? Justified or not, InterMune skyrockets ahead of an FDA panel meeting. |
Salon.com
July 16, 2002
Greg Harrison |
Lawmakers addicted to the quick fix Drug legislation like the proposed RAVE Act does more to promote illicit drug use than discourage it. |
Chemistry World
July 16, 2010
Matt Wilkinson |
Bittersweet victory for GSK's Avandia GlaxoSmithKline has received a muted 'thumbs up' from a US regulatory advisory panel for its much-maligned Type 2 diabetes drug Avandia (rosiglitazone), making it likely the US Food and Drug Administration will allow the UK-based pharma giant to continue selling the drug in the US. |
The Motley Fool
March 31, 2011
Brian Orelli |
Drug Warning Labels: The Good, Bad, and Ugly Once a drug is approved, investors can't fall asleep and ignore FDA announcements about drugs. They come in different varieties, but warnings tend to be of the bad and ugly variety more often than the good. |
The Motley Fool
September 30, 2010
Brian Orelli |
Avoid This Multibillion-Dollar Market It's just too crowded, but there's no doubt that psychiatric drugs are big business for some drugmakers. |
Pharmaceutical Executive
March 1, 2011 |
Pharm Exec's Seventh Annual Media Audit Negative views regarding pharma are on the rise, but vaccines help keep the focus on the positives of innovation. |
The Motley Fool
March 4, 2010
Brian Orelli |
A Painless Drug Deal Bristol-Myers licenses pain drug from Allergan. |
The Motley Fool
May 21, 2010
Brian Orelli |
And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too. |
Chemistry World
March 2011 |
Column: In the pipeline Drug discovery is an inherently risky business. Derek Lowe tries to balance some of the risk equations |
Chemistry World
June 11, 2014
Mark Peplow |
A mind-blowing legacy For some, Alexander Shulgin was a bold explorer at the frontiers of neurochemistry. To others, he was the wanton architect of a wave of dangerous recreational drugs: the godfather of ecstasy. |
Chemistry World
November 2010 |
Column: In the Pipeline Should drug companies focus on big markets and the blockbuster dream? |
The Motley Fool
January 29, 2010
Brian Orelli |
How to Make Billions of Dollars Without Really Trying Lackluster Alzheimer's drugs have been doing it for years. |
Chemistry World
March 23, 2010 |
Comment: Can we halt the flow of new designer drugs? Could the dangers of 'legal high' mephedrone have been predicted? Of course they could, says John Mann |
The Motley Fool
September 14, 2010
Luke Timmerman |
Arena Obesity Drug Effective by "Slim Margin"; Shares Tumble The market is reacting negatively to news about the company's weight-loss drug. |
The Motley Fool
August 10, 2010
Brian Orelli |
When the Disease Matters Most in Drug Approval Glaxo's and Valeant's Potiga will go before an FDA advisory committee tomorrow. |
The Motley Fool
January 12, 2010
Dayana Yochim |
6 Ways to Score Cheap(er) Drugs Stop overpaying for the pills you have to pop with these simple ways to trim your prescription-drug tab. |
American Family Physician
June 1, 2004 |
Club Drugs-Myths and Risks This article provides a general overview on the topic of club drugs like Ecstasy. |
The Motley Fool
November 30, 2010
Brian Orelli |
A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist. |
The Motley Fool
September 8, 2010
Jim Mueller |
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. |
Chemistry World
February 10, 2012
Elinor Richards |
Instant ecstasy detector The probe has been designed to detect the active ingredient in ecstasy - MDMA (3,4-methylenedioxymethamphetamine) - even when it is mixed with other common additives, which has been a challenge. |
The Motley Fool
December 3, 2010
Brian Orelli |
Merck Smartens Up The acquisition of SmartCells looks like an intelligent move. |
Chemistry World
October 1, 2007
Victoria Gill |
Anorexia Shares Addictive Pathway with Ecstasy Researchers in France have discovered that anorexia and MDMA share a common signaling pathway in the brain - both reducing the drive to eat by stimulating the same subset of receptors for the neurotransmitter serotonin. |
The Motley Fool
January 28, 2010
Brian Orelli |
How to Make a Billion Bucks in Biotech Drug companies and investors alike have to balance the risk and reward. |
